The author comments on the commentary by Wilkins on the way in which policy options for new psychoactive substances (NPS) are evaluated in the absence of data. She explores the issue surrounding the use of a medical regime designed for drug (medication) registration. She says that Wilkins side-stepped what she viewed as the fundamental problem associated with a medically oriented regulatory regime.